Will a competitor receive FDA approval for a new RAS-targeted therapy in PDAC by December 31, 2026?
Current Prediction
Why This Question Matters
Competitive position is the core debate between lenses. Moat Mapper classifies COMPETITIVE_POSITION as EMERGING based on platform breadth (4 compounds vs. competitors' 1-2), while Stress Scanner views the same breadth as AGGRESSIVE risk. A competitor PDAC approval would directly narrow RVMD's first-mover advantage and validate the Stress Scanner's concern. No competitor approval would support the Moat Mapper's EMERGING classification.
Prediction Distribution
Individual Predictions(9 runs)
No competitor currently has a KRAS-targeted therapy approved for PDAC. Sotorasib and adagrasib are approved for KRAS G12C NSCLC only. KRAS G12C represents only ~1-2% of PDAC patients, making a PDAC-specific label extension unlikely without dedicated Phase III data. BMS would need positive Phase III data in PDAC plus FDA review — neither is likely to complete by December 2026. Erasca is in Phase 2. Lilly's programs are earlier stage. The timeline is too compressed for any competitor to achieve FDA PDAC approval.
FDA approval requires completed Phase III trials, NDA submission, and FDA review — a multi-year process from the current competitive landscape state. No competitor has completed or is near completing a Phase III trial in PDAC with a RAS-targeted therapy. Even the most advanced competitor (BMS with sotorasib in other indications) has not initiated a dedicated PDAC Phase III. The 9-month window to December 2026 is far too short for any new PDAC approval.
The only plausible path would be an accelerated approval based on impressive Phase II data in PDAC, but even this would require: (1) completion of a compelling Phase II trial, (2) NDA submission, and (3) FDA review — unlikely to all occur by December 2026. A slight upward adjustment for the possibility that an undisclosed competitor program could surprise with breakthrough data and accelerated approval, but this is a tail scenario.
This is nearly impossible within the 2026 timeframe. No competitor has a Phase III-ready PDAC program with RAS-targeted therapy. Sotorasib and adagrasib are G12C-specific (1-2% of PDAC) and lack PDAC-specific data. FDA approval in 9 months from current state is not realistic for any competitor.
The competitive landscape in PDAC KRAS therapy is early stage. BMS has the most advanced infrastructure but no PDAC-specific Phase III. Erasca is Phase 2. Lilly programs are preclinical to early clinical. The fastest possible path (breakthrough designation + accelerated approval) still requires compelling Phase II/III data that doesn't exist yet for PDAC. Probability is low single digits.
Allowing for small probability of surprise: a Chinese biotech with an advanced KRAS program in PDAC might file under Project Orbis or a similar multinational review pathway. But even this would require completed Phase III data and FDA agreement to review — extremely unlikely to culminate in approval by December 2026. The base probability remains under 10%.
No competitor has Phase III data in PDAC for RAS-targeted therapy. Timeline to approval is too compressed. Very low probability.
FDA PDAC approval for a new RAS therapy requires data that doesn't exist. Even accelerated pathways need completed trials. Under 10% probability.
Competitors are years behind RVMD in PDAC-specific development. No realistic path to FDA PDAC approval by December 2026.
Resolution Criteria
Resolves YES if the FDA approves any new RAS-targeted therapy (KRAS or broader RAS inhibitor) with a pancreatic cancer indication by December 31, 2026. Existing KRAS G12C approvals in NSCLC (sotorasib, adagrasib) do not count unless a new PDAC indication is approved. Resolves NO otherwise.
Resolution Source
FDA Drugs@FDA database or FDA press releases
Source Trigger
BMS KRAS G12C data, Erasca Phase 2 data, Lilly KRAS programs — any breakthrough narrows RVMD's first-mover advantage
Full multi-lens equity analysis